Comparative effectiveness of front-line ipilimumab and nivolumab or axitinib and pembrolizumab in metastatic clear cell renal cell carcinoma
Background Treatment of metastatic renal cell carcinoma (mRCC) is rapidly evolving with
new combination therapies demonstrating improved response rates and survival. There are …
new combination therapies demonstrating improved response rates and survival. There are …
Approaches to first-line therapy for metastatic clear cell renal cell carcinoma
Abstract Purpose of Review Four immuno-oncology (IO)-based combinations have
demonstrated overall survival benefit as frontline treatment of metastatic clear cell renal cell …
demonstrated overall survival benefit as frontline treatment of metastatic clear cell renal cell …
Real-world clinical outcomes of patients with metastatic renal cell carcinoma receiving pembrolizumab+ axitinib vs. ipilimumab+ nivolumab
NJ Shah, SD Sura, R Shinde, J Shi, P Singhal… - … Oncology: Seminars and …, 2023 - Elsevier
Abstract Background Immune-Oncology (IO) therapies have changed first-line (1L) treatment
paradigm for metastatic renal cell carcinoma (mRCC) in last few years with robust clinical …
paradigm for metastatic renal cell carcinoma (mRCC) in last few years with robust clinical …
First-line systemic therapy for metastatic clear-cell renal cell carcinoma: critical appraisal of emerging options
Until recently, a dichotomy existed in the front-line approach of metastatic clear-cell renal
cell carcinoma (mRCC). Specifically, patients received either targeted therapy or …
cell carcinoma (mRCC). Specifically, patients received either targeted therapy or …
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up …
4500 Background: In the first interim analysis of the randomized, multicenter, open-label,
phase 3 KEYNOTE-426 study (NCT02853331), treatment with pembro+ axi significantly …
phase 3 KEYNOTE-426 study (NCT02853331), treatment with pembro+ axi significantly …
Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab+ ipilimumab in advanced clear cell renal cell carcinoma (aRCC) …
604 Background: Treatment with immunotherapy can be associated with prolonged disease
control after discontinuation without the need for further anticancer therapy. Toxicity from …
control after discontinuation without the need for further anticancer therapy. Toxicity from …
Overview of current and future first-line systemic therapy for metastatic clear cell renal cell carcinoma
DM Gill, AW Hahn, P Hale, BL Maughan - Current treatment options in …, 2018 - Springer
Opinion statement Treatment of metastatic clear cell renal cancer (mccRCC) has seen
substantial progress over the last 20 years, with many regulatory approvals since 2006 …
substantial progress over the last 20 years, with many regulatory approvals since 2006 …
First-line treatment of metastatic clear cell renal cell carcinoma: what are the most appropriate combination therapies?
YA Vano, S Ladoire, R Elaidi, S Dermeche, JC Eymard… - Cancers, 2021 - mdpi.com
Simple Summary First-line treatment options for metastatic clear cell renal cell carcinoma
have significantly increased. The current recommended therapeutic strategy is based on a …
have significantly increased. The current recommended therapeutic strategy is based on a …
First-line treatments for metastatic clear cell renal cell carcinoma: an ever-enlarging landscape
Abstract Treatment paradigm for metastatic clear cell renal cell carcinoma (mccRCC) has
changed dramatically over the recent decades. From cytokines, interleukin-2 and interferon …
changed dramatically over the recent decades. From cytokines, interleukin-2 and interferon …
Updated European Association of Urology Guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer
T Powles, L Albiges, M Staehler, K Bensalah… - European urology, 2018 - Elsevier
The randomised phase III clinical trial Checkmate-214 showed a survival superiority for the
combination of ipilimumab and nivolumab when compared with the previous standard of …
combination of ipilimumab and nivolumab when compared with the previous standard of …